Qlik to Present at March Conferences

RADNOR, Pa.--(BUSINESS WIRE)-- Qlik, (NASDAQ: QLIK), a leader in visual analytics delivering intuitive solutions for self-service data visualization and guided analytics, today announced Chief Executive Officer, Lars Björk, and Chief Financial Officer, Tim MacCarrick, will present at the JMP Securities Technology Conference in San Francisco on March 1, 2016 at 9:00 a.m. Pacific Time, and the Morgan Stanley Technology, Media & Telecom Conference in San Francisco on March 2, 2016 at 1:20 p.m. Pacific Time. The presentations will be webcast live, and an archive of the presentations will be available for a limited time under the “Events & Presentations” section on the company’s investor relations website (http://investor.qlik.com/).

About Qlik

Qlik (NASDAQ: QLIK) is a leader in visual analytics. Its portfolio of products meets customers' growing needs from reporting and self-service visual analysis to guided, embedded and custom analytics. Approximately 38,000 customers rely on Qlik solutions to gain meaning out of information from varied sources, exploring the hidden relationships within data that lead to insights that ignite good ideas. Headquartered in Radnor, Pennsylvania, Qlik has offices around the world with more than 1,700 partners covering more than 100 countries.

© 2016 QlikTech International AB. All rights reserved. Qlik®, Qlik Sense®, QlikView®, QlikTech®, Qlik® Cloud, Qlik® DataMarket, Qlik® Analytics Platform and the QlikTech logos are trademarks of QlikTech International AB which have been registered in multiple countries. Other marks and logos mentioned herein are trademarks or registered trademarks of their respective owners.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160223005014/en/

Qlik
Investor Contact:
Brett Pollack, 646-561-0906
[email protected]
or
Media Contact:
Maria Scurry, 617-658-5317
[email protected]

Source: Qlik

You May Also Be Interested In

• Sectra publishes Annual Report and Sustainability Report for 2025/2026
• Nonprofit Launches One of the Nation’s Most Comprehensive Education Resources for Inherited Retinal Diseases
• Grünenthal receives FDA Orphan Drug and Rare Pediatric Disease Designations for Tegacorat for the Treatment of Duchenne Muscular Dystrophy